Drugmakers are lobbying the Trump administration and European Union (EU) to exclude medical goods from expanding tariff wars, aiming to prevent price hikes on major European-made medicines. Industry insiders warn that tariffs could increase drug costs, threatening patient access and contradicting U.S. health priorities.
About the Author
